## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

## Listing of Claims:

- (Currently amended) A composition for immobilizing and encapsulating viable and functional cells or bioactive substances comprising: a) liquid polysaccharide solution of isotonic neutral chitosan; and b) a cross-linking solution consisting of a bifunctional or multifunctional, aldehyde or aldehyde treated hydroxyl containing polymer dissolved in physiological media glyoxal.
- (Currently amended) The composition of claim § [[1]], wherein the cross-linking solution
  consists of a bifunctional or multifunctional cross-linker and a hydroxylated polymer of
  appropriate ratio and molecular mass such as to permit the hydroxylated polymer to remain
  liquid in solution.
- (Currently amended) The composition of claim 1, where the cross-linking solution <u>further</u> <u>comprises eonsists of glyoxal, or glyoxal-treated hydroxyethyl cellulose dissolved in a physiological medium.</u>
- 4. (Currently amended) The composition of claim 1, wherein the composition comprises: a) 0.5 to 5.0% by weight chitosan, or chitosan derivative, or poly amine containing polymer; and b) 0.01 to 5.0% by weight hydroxyethyl cellulose, wherein said solution form a gel between temperatures of 4°C and 42°C, said gel providing a physiological environment for maintaining viability of cells.
- (Currently amended) The composition of claim <u>1</u> [[4]], further comprising: c) <u>a</u> bifunctional or multifunctional, aldehyde or aldehyde-treated hydroxyl-containing polymer dissolved in physiological media 0.0001-3% glyoxal.
- (Previously presented) The composition of claim 4, wherein the composition forms a gel within seconds to several hours after mixing (a) and (b).

U.S. Serial No.: 10/521,524

Response to Office Action Mailed 11/01/2007

Response Submitted to USPTO on March 27, 2008

(Currently amended) The composition of claim 1 [[5]], wherein the composition forms a
gel within seconds to several hours after mixing (a) and [[,]] (b) and (e).

ger warm seconds to several nears after mixing (a) and (e)

8. (Previously presented) The composition of claim 4, wherein the solution forms a gel

between temperatures of 20°C and 42°C.

9. (Original) The composition of claim 1, wherein the chitosan is dissolved in dilute acid and

mixed with 1.0 to 2.5% by weight of a salt of polyol consisting of mono-phosphate dibasic

salt, or mono-sulfate salt,

10. (Original) The composition of claim 9, wherein said mono-phosphate dibasic salt is mono-

phosphate dibasic salt of glycerol.

11. (Original) The composition of claim 9, wherein mono-phosphate dibasic salt of glycerol is

selected from the group consisting of glycerol-2-phosphate dibasic salt, sn-glycerol 3-

phosphate dibasic salt and L-glycerol-3-phosphate dibasic salt.

12. (Original) The composition of claim 1, wherein chitosan is further mixed with phosphate

buffer and salt.

13. (Original) The composition of claim 1, further comprising a biologically active factor.

14. (Original) The composition of claim 13, wherein the biologically active factor is selected

from the group consisting of cells, a hormones, a drug, DNA, a bulking agent, a growth

factors, a DNA, DNA-polymer complex, liposomes, a pharmacological agent, a metabolic

factor, an antibody, a nutritive factor, an angiogenic factor, and a radioisotope.

15. (Original) The composition of claim 14, wherein said cells are live cells.

16. (Currently amended) The composition of claim 14, wherein the cells are nucleus pulpopus

pulposus, annulus fibrosis, or a mixture thereof.

17. (Original) The composition of claim 14, wherein the cells are embryonic stem cells or stem

cells derived from a tissue selected from the group consisting of bone marrow, adipose,

muscle, brain, skin, liver, vascular smooth muscle, endothelium, blood, or placenta.

18. (Currently amended) The composition of claim 14, wherein the cells are primary cells,

differentiated cells, genetically modified cells, hybridomas, immortalized cells,

U.S. Serial No.: 10/521,524

Response to Office Action Mailed 11/01/2007

Response Submitted to USPTO on March 27, 2008

transformed cells, tissue fragment cells, organelles, or a mixture thereof, nucleated cells, enucleated cells, germ cells, platelet cells, matrix vesieles, eell vesieles, demineralized bone paste, bone chips, cartilage fragments, or eell fragments or tissue fragments.

- (Original) The composition of claim 14, wherein the cells are autologous cells, allogeneic cells or xenogeneic cells.
- 20. (Withdrawn) The composition of claim 14, wherein the biologically active factor is a cell attachment factor selected from the group consisting of fibrinogen, fibrin, fibronectin, hyaluronic acid, heparin, collagen, polylysine, polyornithine, receptor-binding cyclic peptide, receptor-binding protein.
- (Withdrawn) The composition of claim 14, wherein the biologically active factor is an enzyme, a growth-factor or a growth factor-immobilized substance.
- (Withdrawn) The composition of claim 14, wherein the biologically active factor is a
  plasmid DNA in the form of liposomes, a lipid complex, a chitosan complex, a poly-lysine
  complex, a DEAE dextran complex.
- (Withdrawn) The composition of claim 14, wherein the biologically active factor is a vaccine.
- (Withdrawn) The composition of claim 23, wherein the vaccine comprises an infective viral particle.
- (Withdrawn) The composition of claim 14, wherein the biologically active factor is a nutritive or metabolic factor.
- 26. (Withdrawn) The composition of claim 25, wherein the a nutritive or metabolic factor is a lipid, amino acids, and a co-factor selected from the group consisting of cholesterol, glutamine, glucosamine, ascorbic acid, pyruvate, and lactate.
- 27. (Withdrawn) The composition of claim 14, wherein the biologically active factor is at least one element selected from the group consisting of peripheral blood, bone blood, cord blood, a blood product, blood-borne cells, serum, platelets, platelet-rich plasma, fibrinogen, a clotting factor, and a blood-borne enzyme.

U.S. Serial No.: 10/521,524

Response to Office Action Mailed 11/01/2007

Response Submitted to USPTO on March 27, 2008

28. (Withdrawn) The composition of claim 14, wherein the biologically active factor is an

osteogenic substance,

29. (Withdrawn) The composition of claim 28, wherein the osteogenic substance is a member

of the bone morphogenetic protein family selected from the group consisting of TGF- $\beta 1$ ,

BMP-2, BMP-6, BMP-7, or a mixture thereof.

30. (Original) The composition in claim 1, wherein hydroxyl-containing polymer is polyvinyl

alcohol, dextran, linked with a bifunctional reactive aldehyde.

31. – 40. (Canceled)

41. (Withdrawn) A method for repairing soft tissue, said method comprising the step of

administering the composition of claim 1 at the site of a soft tissue in need of repair of a

patient.

42. (Withdrawn) A method for repairing or resurfacing a damaged cartilage, said method

comprising the step of administering the composition of claim 1 in or around a cartilage in

need of repair or resurfacing of a patient.

 (Withdrawn) A method for repairing a meniscus of a patient, said method comprising the step of administering the composition of claim 1 at the site of the meniscus in need of

.

repair.

 (Original) The composition of claim 3, where the physiological medium comprises cell nutrients selected from the group consisting of glucose, amino acids, and vitamins, or a

combination thereof, at isotonic and neutral pH.